{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:42:46Z","timestamp":1785897766278,"version":"3.56.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43TW009118"],"award-info":[{"award-number":["D43TW009118"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.metabol.2026.156668","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:07:27Z","timestamp":1780985247000},"page":"156668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Benefits and harms of antiresorptive therapy in men with non-metastatic prostate cancer on androgen deprivation therapy: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"182","author":[{"given":"Aya","family":"Bassatne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"El Meski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Horanieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Andary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caline","family":"Rhayem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Mukherji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie A.","family":"Akl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"El-Hajj Fuleihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Chakhtoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.metabol.2026.156668_bb0005","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2026.156668_bb0010","first-page":"S3","article-title":"Androgen deprivation therapy in the treatment of advanced prostate cancer","volume":"9 Suppl 1","author":"Perlmutter","year":"2007","journal-title":"Rev Urol"},{"issue":"43","key":"10.1016\/j.metabol.2026.156668_bb0015","doi-asserted-by":"crossref","first-page":"75646","DOI":"10.18632\/oncotarget.17980","article-title":"The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation","volume":"8","author":"Cianferotti","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.metabol.2026.156668_bb0020","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3390\/cancers12061529","article-title":"Pathophysiology of bone loss in patients with prostate cancer receiving androgen-deprivation therapy and lifestyle modifications for the management of bone health: a comprehensive review","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.metabol.2026.156668_bb0025","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2026.156668_bb0030","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.metabol.2026.156668_bb0035","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.metabol.2026.156668_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8010113","article-title":"Effect of androgen-deprivation therapy on bone mineral density in patients with prostate cancer: a systematic review and meta-analysis","volume":"8","author":"Kim","year":"2019","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.metabol.2026.156668_bb0045","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0022-5347(05)65060-4","article-title":"Osteoporosis in men treated with androgen deprivation therapy for prostate cancer","volume":"167","author":"Ross","year":"2002","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.metabol.2026.156668_bb0050","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs","volume":"87","author":"Mittan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2026.156668_bb0055","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.3747\/co.v18i4.746","article-title":"A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy","volume":"18","author":"Lee","year":"2011","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.metabol.2026.156668_bb0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.juro.2006.08.089","article-title":"Bone health in men receiving androgen deprivation therapy for prostate cancer","volume":"177","author":"Eastham","year":"2007","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.metabol.2026.156668_bb0065","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1359\/jbmr.090419","article-title":"Loss of hip BMD in older men: the osteoporotic fractures in men (MrOS) study","volume":"24","author":"Cawthon","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.metabol.2026.156668_bb0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bju.14015","article-title":"Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures","volume":"121","author":"Poon","year":"2018","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.metabol.2026.156668_bb0075","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/M16-2577","article-title":"Bone health and bone-targeted therapies for nonmetastatic prostate cancer: a systematic review and meta-analysis","volume":"167","author":"Alibhai","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.metabol.2026.156668_bb0080","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.euo.2018.11.001","article-title":"Preventing osteoporosis in men taking androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"2","author":"Joseph","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.metabol.2026.156668_bb0085","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.eururo.2012.09.007","volume":"63","author":"Klotz","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.metabol.2026.156668_bb0090","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.metabol.2026.156668_bb0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000115412","article-title":"Prevention of bone mineral loss by zoledronic acid in men with prostate carcinoma receiving androgen deprivation therapy: a prospective randomized trial in an Indian population","volume":"2","author":"Rao","year":"2008","journal-title":"Current Urology"},{"issue":"4","key":"10.1016\/j.metabol.2026.156668_bb0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3816\/CGC.2007.n.003","article-title":"The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy","volume":"5","author":"Israeli","year":"2007","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.metabol.2026.156668_bb0105","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","article-title":"Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer","volume":"176","author":"Ryan","year":"2006","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.metabol.2026.156668_bb0110","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.metabol.2026.156668_bb0115","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156668_bb0120","series-title":"Benefits and harms of antiresorptive therapy in men with non-metastatic prostate cancer on androgen deprivation therapy: a systematic review and meta-analysis of randomized controlled trials","author":"Bassatne","year":"2021"},{"issue":"1","key":"10.1016\/j.metabol.2026.156668_bb0125","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jclinepi.2010.07.007","article-title":"Which fractures are most attributable to osteoporosis?","volume":"64","author":"Warriner","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.metabol.2026.156668_bb0130","series-title":"Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019)","author":"Higgins","year":"2019"},{"key":"10.1016\/j.metabol.2026.156668_bb0135","series-title":"GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013","year":"2013"},{"issue":"4","key":"10.1016\/j.metabol.2026.156668_bb0140","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"8","key":"10.1016\/j.metabol.2026.156668_bb0145","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"18","key":"10.1016\/j.metabol.2026.156668_bb0150","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.metabol.2026.156668_bb0155","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.metabol.2026.156668_bb0160","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2026.156668_bb0165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2026.156668_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2026.156668_bb0175","series-title":"McMasterUniversity Grade Pro GDT","year":"2014"},{"issue":"7650","key":"10.1016\/j.metabol.2026.156668_bb0180","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Bmj"},{"issue":"5","key":"10.1016\/j.metabol.2026.156668_bb0185","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ijrobp.2012.11.007","article-title":"Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy","volume":"85","author":"Choo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.metabol.2026.156668_bb0190","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/j.1464-410X.2010.09329.x","article-title":"Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer","volume":"106","author":"Taxel","year":"2010","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.metabol.2026.156668_bb0195","first-page":"321","article-title":"Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8","volume":"18","author":"Kearns","year":"2010","journal-title":"Support Care Cancer"},{"issue":"27","key":"10.1016\/j.metabol.2026.156668_bb0200","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1200\/JCO.2007.15.1233","article-title":"Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.metabol.2026.156668_bb0205","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00198-019-05271-5","volume":"31","author":"Yoshida","year":"2020","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.metabol.2026.156668_bb0210","first-page":"195","article-title":"Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study","volume":"13","author":"Doria","year":"2016","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"3","key":"10.1016\/j.metabol.2026.156668_bb0215","first-page":"271","article-title":"Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate","volume":"69","author":"Doria","year":"2016","journal-title":"Minerva Urologica e Nefrologica = Ital J Urol Nephrol"},{"issue":"10","key":"10.1016\/j.metabol.2026.156668_bb0220","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/jbmr.4106","article-title":"Differing effects of Zoledronic acid on bone microarchitecture and bone mineral density in men receiving androgen deprivation therapy: a randomized controlled trial","volume":"35","author":"Cheung","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2026.156668_bb0225","doi-asserted-by":"crossref","DOI":"10.1177\/20420188211012118","article-title":"Zoledronic acid does not affect insulin resistance in men receiving androgen deprivation therapy: a prespecified secondary analysis of a randomised controlled trial","volume":"12","author":"Cheung","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2026.156668_bb0230","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.eururo.2014.02.014","article-title":"Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)","volume":"67","author":"Wirth","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.metabol.2026.156668_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2193-1801-3-586","article-title":"Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade","volume":"3","author":"Nishizawa","year":"2014","journal-title":"Springerplus"},{"issue":"10","key":"10.1016\/j.metabol.2026.156668_bb0240","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1470-2045(14)70328-6","volume":"15","author":"Denham","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.metabol.2026.156668_bb0245","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bju.12497","volume":"114","author":"Denham","year":"2014","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.metabol.2026.156668_bb0250","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/pcan.2013.35","article-title":"RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients","volume":"16","author":"Kachnic","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.metabol.2026.156668_bb0255","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/176164","article-title":"Effect of zoledronic acid on bone mineral density in men with prostate cancer receiving gonadotropin-releasing hormone analog","volume":"2011","author":"Kapoor","year":"2011","journal-title":"Prostate Cancer"},{"issue":"3","key":"10.1016\/j.metabol.2026.156668_bb0260","first-page":"5170","article-title":"Long term zoledronic acid during androgen blockade for prostate cancer","volume":"17","author":"Casey","year":"2010","journal-title":"Can J Urol"},{"issue":"5","key":"10.1016\/j.metabol.2026.156668_bb0265","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.juro.2009.07.046","article-title":"Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy","volume":"182","author":"Bhoopalam","year":"2009","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.metabol.2026.156668_bb0270","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist\u2013induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.metabol.2026.156668_bb0275","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1464-410X.2007.06853.x","article-title":"Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid","volume":"100","author":"Ryan","year":"2007","journal-title":"BJU Int"},{"issue":"13","key":"10.1016\/j.metabol.2026.156668_bb0280","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.metabol.2026.156668_bb0285","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.eururo.2005.01.012","article-title":"Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate","volume":"47","author":"Magno","year":"2005","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.metabol.2026.156668_bb0290","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1359\/JBMR.040813","article-title":"Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer","volume":"19","author":"Morabito","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"9810","key":"10.1016\/j.metabol.2026.156668_bb0295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"issue":"30","key":"10.1016\/j.metabol.2026.156668_bb0300","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis\u2013free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.metabol.2026.156668_bb0305","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1002\/jbmr.492","article-title":"Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer","volume":"26","author":"Smith","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.metabol.2026.156668_bb0310","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.juro.2009.08.048","article-title":"Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer","volume":"182","author":"Smith","year":"2009","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.metabol.2026.156668_bb0315","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/pcan.2012.18","article-title":"Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer","volume":"15","author":"Egerdie","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.metabol.2026.156668_bb0320","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","article-title":"Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer","volume":"176","author":"Ryan","year":"2006","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.metabol.2026.156668_bb0325","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.eururo.2012.09.007","volume":"63","author":"Klotz","year":"2013","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.metabol.2026.156668_bb0330","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/oncolo\/oyac213","article-title":"Bone health and denosumab discontinuation in oncology populations","volume":"27","author":"Cheung","year":"2022","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.metabol.2026.156668_bb0335","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.metabol.2026.156668_bb0340","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.7314\/APJCP.2013.14.5.3337","article-title":"Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis","volume":"14","author":"Ding","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"10.1016\/j.metabol.2026.156668_bb0345","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/pcan.2011.4","article-title":"Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"15","author":"Serpa Neto","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"10.1016\/j.metabol.2026.156668_bb0350","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s40520-023-02478-9","article-title":"Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis","volume":"35","author":"Beaudart","year":"2023","journal-title":"Aging Clin Exp Res"},{"issue":"11","key":"10.1016\/j.metabol.2026.156668_bb0355","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S2213-8587(20)30340-5","article-title":"Bone mineral density as a surrogate biomarker for fracture risk reduction\u2013authors\u2019 reply","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.metabol.2026.156668_bb0360","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00198-009-0838-9","article-title":"Bone turnover markers: understanding their value in clinical trials and clinical practice","volume":"20","author":"Civitelli","year":"2009","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.metabol.2026.156668_bb0365","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.metabol.2026.156668_bb0370","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jbmr.3355","article-title":"Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of anti-resorptive drugs: a meta-regression","volume":"33","author":"Bauer","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.metabol.2026.156668_bb0375","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jbmr.4178","article-title":"Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of antiresorptive drugs: proportion of treatment effect explained","volume":"36","author":"Eastell","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10.1016\/j.metabol.2026.156668_bb0380","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1359\/jbmr.07090b","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis","volume":"22","author":"Eastell","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.metabol.2026.156668_bb0385","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials","volume":"19","author":"Qi","year":"2014","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.metabol.2026.156668_bb0390","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00198-010-1177-6","article-title":"Denosumab-related osteonecrosis of the jaws","volume":"22","author":"Kyrgidis","year":"2011","journal-title":"Osteoporos Int"},{"issue":"35","key":"10.1016\/j.metabol.2026.156668_bb0395","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1200\/JCO.2017.73.7437","article-title":"Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (alliance)","volume":"35","author":"Shapiro","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526001782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526001782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:17:55Z","timestamp":1784708275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049526001782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":79,"alternative-id":["S0026049526001782"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156668","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits and harms of antiresorptive therapy in men with non-metastatic prostate cancer on androgen deprivation therapy: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156668"}}